QTORIN rapamycin

WAYNE, Pa., May 15, 2026 Palvella Therapeutics announced new positive Phase 2 TOIVA trial data for QTORIN™ rapamycin in...

WAYNE, Pa., Feb. 24, 2026 — Palvella Therapeutics announced positive topline results from its Phase 3 SELVA clinical study...